SG11201807912SA - Vaccine against rsv - Google Patents

Vaccine against rsv

Info

Publication number
SG11201807912SA
SG11201807912SA SG11201807912SA SG11201807912SA SG11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA
Authority
SG
Singapore
Prior art keywords
international
archimedesweg
leiden
rsv
pct
Prior art date
Application number
SG11201807912SA
Inventor
Johannes Langedijk
Janneke Verhagen
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11201807912SA publication Critical patent/SG11201807912SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 011101011101111101100 1111 DIM III International Bureau ... .... ..Yjd (10) International Publication Number ..... ...,/ (43) International Publication Date WO 2017/174564 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: A61K 39/12 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: PCT/EP2017/057957 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: 4 April 2017 (04.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: 16163807.7 5 April 2016 (05.04.2016) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: LANGEDIJK, Johannes, Petrus, Maria; Archimedesweg 4-6, 2333 CN Leiden (NL). VERHA- GEN, Janneke, M; Archimedesweg 4-6, 2333 CN Leiden SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (NL). — as to applicant's entitlement to apply for and be granted a — (74) Agents: MANTEN, Annemieke et al.; Archimedesweg 4- 6, 2333 CN Leiden (NL). patent (Rule 4.17(11)) — of inventorship (Rule 4.17(iv)) = (81) Designated States (unless otherwise indicated, for every Published: kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — with international search report (Art. 21(3)) = = = = = = = = = = = = 1-1 7r ,tD 1 1 in IN ,—, IN IN 1-1 (54) Title: VACCINE AGAINST RSV 0 ei (57) : The present invention relates to novel nucleic acid molecules encoding a pre- fusion RSV F protein or immunologic - en. ) ally active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The inven - '' ,... °. tion further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).
SG11201807912SA 2016-04-05 2017-04-04 Vaccine against rsv SG11201807912SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163807 2016-04-05
PCT/EP2017/057957 WO2017174564A1 (en) 2016-04-05 2017-04-04 Vaccine against rsv

Publications (1)

Publication Number Publication Date
SG11201807912SA true SG11201807912SA (en) 2018-10-30

Family

ID=55661317

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807912SA SG11201807912SA (en) 2016-04-05 2017-04-04 Vaccine against rsv

Country Status (18)

Country Link
US (3) US10729757B2 (en)
EP (1) EP3439694A1 (en)
JP (2) JP7233928B2 (en)
KR (3) KR102500970B1 (en)
CN (1) CN109069612A (en)
AU (1) AU2017248018A1 (en)
BR (1) BR112018070323A2 (en)
CA (1) CA3018139A1 (en)
CL (1) CL2018002825A1 (en)
EA (1) EA201892250A1 (en)
IL (1) IL262109B2 (en)
MA (1) MA43762A (en)
MX (1) MX2018012095A (en)
MY (1) MY193584A (en)
PE (1) PE20190433A1 (en)
PH (1) PH12018501912A1 (en)
SG (1) SG11201807912SA (en)
WO (1) WO2017174564A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201902513T4 (en) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion RSV F polypeptides.
EA035909B1 (en) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Stabilized soluble pre-fusion rsv f polypeptides
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V Vaccine against rsv
WO2017070626A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Respiratory virus vaccines
CN109069616A (en) * 2016-04-05 2018-12-21 扬森疫苗与预防公司 RSV F protein before stabilized soluble fusion
SG11201807912SA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Vaccine against rsv
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
EP3624844A1 (en) * 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
MA54676A (en) * 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
EP3969045A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
WO2020229577A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
JP2023531554A (en) 2020-06-29 2023-07-24 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine Combinations Against Respiratory Syncytial Virus Infection
CN112220921B (en) * 2020-08-25 2022-08-16 北京交通大学 Combined vaccine for respiratory syncytial virus infection
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN114277039B (en) * 2021-10-25 2024-06-21 浙江君怡生物科技有限公司 Respiratory syncytial virus mRNA vaccine and preparation method and application thereof
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
TW202424187A (en) 2022-10-27 2024-06-16 美商輝瑞大藥廠 Rna molecules
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
CN118078975A (en) * 2023-03-17 2024-05-28 成都威斯克生物医药有限公司 Vaccine against respiratory syncytial virus infection

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
WO1997000326A1 (en) 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000514290A (en) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー Method for producing recombinant adenovirus
FR2751343B1 (en) 1996-07-16 1998-12-18 Transgene Sa PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
ES2278399T3 (en) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS.
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CA2320419C (en) 1998-02-17 2011-02-08 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
DK1133316T3 (en) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus formulation for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
DK1550722T3 (en) 1999-05-17 2007-10-08 Crucell Holland Bv Recombinant human adenovirus serotype 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2001085984A1 (en) 2000-05-08 2001-11-15 Davisco Foods International, Inc. Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
JP5118798B2 (en) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション Adenovirus preparation
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Composition for the preservation of viruses
WO2003061708A1 (en) 2002-01-18 2003-07-31 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
PT1497438E (en) 2002-04-25 2010-02-04 Crucell Holland Bv Means and methods for the production of adenovirus vectors
PT1506287E (en) 2002-05-14 2007-07-17 Merck & Co Inc Methods of adenovirus purification
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2337374T3 (en) 2004-01-23 2010-04-23 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. CHINPANCE ADENOVIRUS VACCINE CARRIERS.
CA2555412C (en) 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
EP2099486A2 (en) * 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
CN101952321B (en) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 Recombinant RSV incorporate antigen
AU2009218462B2 (en) 2008-02-29 2015-02-05 Tibotec Pharmaceuticals Method for identifying inhibitors against viruses that use a class I fusion protein
ES2532015T3 (en) 2008-11-03 2015-03-23 Crucell Holland B.V. Method for the production of adenoviral vectors
CN106146671B (en) 2008-12-09 2020-03-31 诺瓦瓦克斯股份有限公司 Modified RSV F proteins and methods of use thereof
CN102300872A (en) 2009-02-02 2011-12-28 奥凯罗斯股份公司 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA2766205A1 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
PE20121541A1 (en) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa RECOMBINANT RESPIRATORY SYNCIZAL VIRUS ANTIGENS
PL3178490T3 (en) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Rsv f protein compositions and methods for making same
SG178335A1 (en) 2009-08-13 2012-03-29 Crucell Holland Bv Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2488636B1 (en) 2009-10-15 2014-03-12 Crucell Holland B.V. Method for the purification of adenovirus particles from high cell density cultures
WO2011045381A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
EA023816B1 (en) 2010-02-15 2016-07-29 Круселл Холланд Б.В. METHOD FOR THE PRODUCTION OF Ad26 VIRUS PARTICLES
BR112012031638B1 (en) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anti-rsv antibody or antigen binding fragment thereof, multivalent antibody, pharmaceutical composition, use of antibody or antigen binding fragment, method of detecting rsv infection, and isolated nucleic acid
RS56748B1 (en) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (en) 2012-03-12 2016-10-31 Batches of recombinant adenovirus with altered terminal ends
AU2013237424B2 (en) 2012-03-22 2017-07-06 Janssen Vaccines & Prevention B.V. Vaccine against RSV
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
JP6210998B2 (en) 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 Infectious disease prevention method by combined use of vector vaccine and live vaccine
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CA2902877A1 (en) 2013-03-13 2014-10-02 Jeffrey Boyington Prefusion rsv f proteins and their use
EP3567051A1 (en) 2013-04-15 2019-11-13 Janssen Vaccines & Prevention B.V. Human antibodies binding to rsv g protein
AU2014255865B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
TR201902513T4 (en) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion RSV F polypeptides.
CA2914792C (en) * 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
CN111514314A (en) 2013-09-19 2020-08-11 扬森疫苗与预防公司 Improved adenovirus formulations
JP6664338B2 (en) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic combination
EA035909B1 (en) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Stabilized soluble pre-fusion rsv f polypeptides
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V Vaccine against rsv
CN109069616A (en) 2016-04-05 2018-12-21 扬森疫苗与预防公司 RSV F protein before stabilized soluble fusion
SG11201807912SA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Vaccine against rsv
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
BR112021008975A2 (en) 2018-11-13 2021-08-17 Janssen Vaccines & Prevention B.V. stabilized pre-fusion rsv f proteins
JP2022530439A (en) 2019-04-25 2022-06-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー Recombinant influenza antigen
EP3969045A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
BR112022019411A2 (en) 2020-04-02 2022-12-06 Janssen Vaccines & Prevention Bv STABILIZED VACCINE COMPOSITIONS
JP2023531554A (en) 2020-06-29 2023-07-24 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine Combinations Against Respiratory Syncytial Virus Infection

Also Published As

Publication number Publication date
BR112018070323A2 (en) 2019-01-29
JP2023029889A (en) 2023-03-07
US20200360506A1 (en) 2020-11-19
CN109069612A (en) 2018-12-21
PH12018501912A1 (en) 2019-06-17
US20220288186A1 (en) 2022-09-15
KR20220075436A (en) 2022-06-08
IL262109B2 (en) 2023-04-01
AU2017248018A1 (en) 2018-09-27
KR102491447B1 (en) 2023-01-20
KR20220018618A (en) 2022-02-15
EA201892250A1 (en) 2019-03-29
US10729757B2 (en) 2020-08-04
KR102401247B1 (en) 2022-05-25
IL262109A (en) 2018-11-29
JP2019510497A (en) 2019-04-18
MY193584A (en) 2022-10-19
KR102500970B1 (en) 2023-02-17
PE20190433A1 (en) 2019-03-21
KR20180132761A (en) 2018-12-12
MX2018012095A (en) 2019-01-10
IL262109B (en) 2022-12-01
EP3439694A1 (en) 2019-02-13
US20190125854A1 (en) 2019-05-02
US11801297B2 (en) 2023-10-31
CL2018002825A1 (en) 2018-11-16
US11338031B2 (en) 2022-05-24
JP7233928B2 (en) 2023-03-07
CA3018139A1 (en) 2017-10-12
WO2017174564A1 (en) 2017-10-12
MA43762A (en) 2021-04-21

Similar Documents

Publication Publication Date Title
SG11201807912SA (en) Vaccine against rsv
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201901351UA (en) A patient interface, system and method
SG11201909011PA (en) Niraparib compositions
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201805001UA (en) Method of treating influenza a
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form